Current and future drug therapies for alcohol dependence

Journal of Clinical Psychopharmacology

Volumn 26, Issue 6 SUPPL. 1, 2006, Pages

  Rosenthal, Richard N ^a  

^a St Luke's Roosevelt Hospital Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; AMISULPRIDE; ANTICONVULSIVE AGENT; DISULFIRAM; FLUOXETINE; HALOPERIDOL; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; VIVITROL;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; ASTHENIA; BEHAVIOR THERAPY; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COGNITIVE THERAPY; CONFERENCE PAPER; CONSTIPATION; DECREASED APPETITE; DIAPHORESIS; DIARRHEA; DIZZINESS; FATIGUE; FLATULENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INJECTION SITE PAIN; INSOMNIA; LIVER TOXICITY; MEMORY DISORDER; NAUSEA; NERVOUSNESS; NEURITIS; OPTIC NEURITIS; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; PSYCHOMOTOR RETARDATION; PSYCHOSIS; PSYCHOSOCIAL CARE; RASH; RELAPSE; SIDE EFFECT; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 33751094313     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.000246223.94119.cd     Document Type: Conference Paper

References (75)

1. Substance Abuse and Mental Health Services Administration. Overview of Findings from the 2004 National Survey on Drug Use and Health. DHHS Publication No. SMA 05-4061. Rockville, MD; 2005.
2. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction. 1996;91:1773-1796.
3. Swift RM. Medications. In: Hester RK, Miller WR, eds. Handbook of Alcoholism Treatment Approaches, Effective Alternatives. Boston, MA: Pearson Education, Inc; 2003:259-281.
4. Longabaugh R, Morgenstern J. Cognitive-behavioral coping-skills therapy for alcohol dependence. Current status and future directions. Alcohol Res Health. 1999;23:78-85.
5. Schaffer A, Naranjo CA. Recommended drug treatment strategies for the alcoholic patient. Drugs. 1998;56:571-585.
6. Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother. 2005;6:2103-2115.
7. O'Malley SS, Carroll KM. Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res. 1996;20:17A-22A.
8. Pettinati HM, Volpicelli JR, Pierce JD Jr, et al. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19:71-83.
9. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
10. Swift RM. Drug therapy for alcohol dependence. N Engl J Med. 1999;340:1482-1490.
11. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256:1449-1455.
12. Brewer C, Hardt F. Preventing disulfiram hepatitis in alcohol abusers: inappropriate guidelines and the significance of nickel allergy. Addict Biol. 1999;4:303-308.
13. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161:84-89.
14. De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2005;40:545-548.
15. Brewer C, Streel E. Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive "immersion" methods of foreign language teaching. Subst Abus. 2003;24:157-173.
16. Gianoulakis C. Endogenous opioids and excessive alcohol consumption. J Psychiatry Neurosci. 1993;18:148-156.
17. Heimer L, Alheid GF. Piecing together the puzzle of basal forebrain anatomy. Adv Exp Med Biol. 1991;295:1-42.
18. Roberts AJ, McDonald JS, Heyser CJ, et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther. 2000;293:1002-1008.
19. Gianoulakis C, Beliveau D, Angelogianni P, et al. Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 1989;45:1097-1099.
20. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry. 1996;53:250-257.
21. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993;621:137-140.
22. Gessa GL, Muntoni F, Collu M, et al. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res. 1985;348:201-203.
23. Monti PM, Rohsenow DJ, Hutchison KE, et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999;23:1386-1394.
24. Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res. 1996;20:732-739.
25. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130-1135.
26. Anton RF, Swift RM. Current pharmacotherapies of alcoholism: a US perspective. Am J Addict. 2003;12(suppl 1):S53-S68.
27. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
28. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881-887.
29. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
30. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000;22:493-503.
31. Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99:811-828.
32. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005;8:267-280.
33. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
34. Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl. 2005:148-156.
35. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63.
36. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-1625.
37. Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res. 2004;28:1356-1361.
38. Gastfriend DR, Dong Q, Loewy J, et al. Durability of effect of long-acting injectable naltrexone. Presented at: The American Psychiatric Association Institute, October 5-9, 2005; San Diego, CA.
39. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051-1059.
40. De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav. 2004;29:1325-1339.
41. Kumari M, Ticku MK. Regulation of NMDA receptors by ethanol. Prog Drug Res. 2000;54:152-189.
42. Hoffman PL. NMDA receptors in alcoholism. Int Rev Neurobiol. 2003;56:35-82.
43. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. II Part, Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22:810-814.
44. Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35:331-345.
45. Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038-1053.
46. Acamprosate. Drugs R D. 2002;3:13-18.
47. Pelc I, Verbanck P, O Le Bon, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
48. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
49. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
50. Gage A, Chabac S, Goodman A. Acamprosate is effective for the treatment of alcohol dependence: reanalysis of three pivotal studies. (abstract) Alcohol Clin Exp Res. 2005;29:161A.
51. Schneider E, Saikali K, Zhang D, et al. Efficacy of acamprosate in regaining abstinence in alcohol-dependent patients who relapse (abstract). Presented at: The Academy of Addiction Psychiatry 16th Annual Meeting and Symposium; December 8-11, 2005; Scottsdale, AZ.
52. Mason BJ, Goodman A, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatric Res. 2006;40:383-393.
53. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. 2001;36:413-418.
54. Chick J, Lehert P, Landron F. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol. 2003;17:397-402.
55. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-99.
56. Feeney GF, Connor JP, Young RM, et al. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006;41:321-327.
57. Kranzler HR. Evidence-based treatments for alcohol dependence: new results and new questions. JAMA. 2006;295:2075-2076.
58. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887-1896.
59. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391-397.
60. Kranzler HR, Burleson JA, Brown J, et al. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20:1534-1541.
61. Dundon W, Lynch KG, Pettinati HM, et al. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res. 2004;28:1065-1073.
62. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284:963-971.
63. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
64. Di Chiara G, Imperato A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur J Pharmacol. 1985;115:131-132.
65. Diana M, Pistis M, Muntoni A, et al. Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence. Neuroscience. 1996;71:411-415.
66. Fulton MK, Kramer G, Moeller FG, et al. Low plasma homovanillic acid levels in recently abstinent alcoholic men. Am J Psychiatry. 1995;152:1819-1820.
67. Enggasser JL, de Wit H. Haloperidol reduces stimulant and reinforcing effects of ethanol in social drinkers. Alcohol Clin Exp Res. 2001;25:1448-1456.
68. Modell JG, Mountz JM, Glaser FB, et al. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res. 1993;17:234-240.
69. Hutchison KE, Swift R, Rohsenow DJ, et al. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl). 2001;155:27-34.
70. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441-449.
71. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20:94-98.
72. Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004;28:736-745.
73. Marra D, Warot D, Berlin I, et al. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2002;26:1545-1552.
74. Wiesbeck GA, Weijers HG, Lesch OM, et al. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol. 2001;36:329-334.
75. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210-218.